bi 409306
Small moleculeexperimental
Clinical trial activity
23 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
18
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2011 (NCT01343706)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 9AINHIBITOR
PDE9A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bi 409306
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04602221 | Phase 1 | Dec 1, 2020 | Boehringer Ingelheim |
| NCT03934203 | Phase 1 | May 9, 2019 | Boehringer Ingelheim |
| NCT03505151 | Phase 1 | Apr 27, 2018 | Boehringer Ingelheim |
| NCT03351244 | Phase 2 | Dec 7, 2017 | Boehringer Ingelheim |
| NCT03230097 | Phase 2 | Sep 29, 2017 | Boehringer Ingelheim |
| NCT03193307 | Phase 1 | Jul 5, 2017 | Boehringer Ingelheim |
| NCT03151499 | Phase 1 | May 30, 2017 | Boehringer Ingelheim |
| NCT02853136 | Phase 1 | Aug 25, 2016 | Boehringer Ingelheim |
| NCT02635750 | Phase 1 | Jan 1, 2016 | Boehringer Ingelheim |
| NCT02597998 | Phase 1 | Sep 1, 2015 | Boehringer Ingelheim |
| NCT02438683 | Phase 1 | May 1, 2015 | Boehringer Ingelheim |
| NCT02392468 | Phase 1 | Apr 15, 2015 | Boehringer Ingelheim |
| NCT02337907 | Phase 2 | Jan 21, 2015 | Boehringer Ingelheim |
| NCT02240693 | Phase 2 | Jan 15, 2015 | Boehringer Ingelheim |
| NCT02281773 | Phase 2 | Nov 1, 2014 | Boehringer Ingelheim |
| NCT02248259 | Phase 1 | Oct 1, 2014 | Boehringer Ingelheim |
| NCT02222168 | Phase 1 | Sep 1, 2014 | Boehringer Ingelheim |
| NCT01892384 | Phase 1 | Jun 1, 2013 | Boehringer Ingelheim |
| NCT01841112 | Phase 1 | Apr 1, 2013 | Boehringer Ingelheim |
| NCT01611311 | Phase 1 | May 1, 2012 | Boehringer Ingelheim |
Showing 20 of 23 trials
Page 1 / 2
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 23 | 23 | 2 | 2011 |
1 organizations
Page 1 / 1